Johnson & Johnson

Delhi HC denies Johnson & Johnson subsidiary to sell existing ORSL stock

The Delhi High Court declined interim relief to JNTL Consumer Health, Johnson & Johnson's Indian arm, to sell its remaining ORSL stock, upholding the FSSAI order against misleading branding

J&J ordered to pay record $966 million in talc baby powder cancer case

The verdict comes amid over 70,000 pending claims accusing J&J of talc-related cancers, with many cases consolidated before a federal judge in New Jersey for pre-trial proceedings

Dr Reddy's signs pact with J&J to acquire vertigo treatment brand

Dr Reddy's Laboratories on Thursday announced the completion of a definitive transaction with Johnson & Johnson to acquire Stugeron brand across the EMEA regions, with India and Vietnam as key markets. Stugeron contains Cinnarizine, an antihistamine indicated for the treatment of vestibular disturbances and vertigo. The acquisition presents a strategic opportunity for the Hyderabad-based drug firm to expand its footprint in the anti-vertigo space as well as strengthen its Central Nervous System (CNS) portfolio, Dr Reddy's Laboratories said in a statement. Dr Reddy's acquisition of the brand reflects a steady advancement in the company's efforts to expand into the anti-vertigo therapeutic segment, contributing to the continued development of CNS portfolio, said MV Ramana, CEO, Branded Markets (India and Emerging Markets), Dr Reddy's Laboratories. "Backed by our strong market access, we intend to extend the reach of Stugeron and its associated products across 18 key markets in the ..

Johnson & Johnson increases US investment to over $55 bn over next 4 yrs

Johnson and Johnson, US healthcare's leading, most comprehensive innovation powerhouse, announced on Friday that it will invest more than USD 55 billion in manufacturing, research and development, and technology in the United States over the next four years.According to Johnson and Johnson's statement, this represents a 25 per cent increase in investment compared to the previous four years and builds upon the Company's already elevated US investment levels resulting from the passage of the 2017 Tax Cuts & Jobs Act."Today's announcements accelerate our nearly 140-year legacy as an American innovation engine tackling the world's toughest healthcare challenges," said Joaquin Duato, Chairman and Chief Executive Officer of Johnson and Johnson. "Our increased US investment begins with the ground-breaking of a high-tech facility in North Carolina that will not only add US-based jobs but manufacture cutting-edge medicines to treat patients in America and around the world."In addition to

J&J reports Q4 sales, profit above estimates on cancer drug sales

The New Jersey-based drugmaker expects 2025 sales of between $90.9 billion and $91.7 billion, and to earn between $10.75 and $10.95 per share

J&J to acquire drugmaker Intra-Cellular Therapies for $14.6 billion

The deal is the latest in a string of acquisitions by J&J as it looks to drive growth beyond 2025

J&J Q3 earnings beat expectations, make progress on talc liabilities

Adjusted profit was $2.42 a share, surpassing Wall Street's average estimate of $2.19. Pharmaceutical revenue rose almost 5 per cent, exceeding expectations by more than $400 million

J&J raises baby powder settlement offer to more than $8.2 billion

J&J recently garnered support from more than 75 per cent of baby powder claimants for an out-of-court deal that includes claims that the talc-based version caused ovarian and other gynecological cance

Johnson & Johnson to pay additional $1.1 bn to resolve talc settlement

The increase would boost the size of the settlement to more than $9 billion paid over 25 years

J&J gets plaintiff backing for $6.5 bn to resolve lawsuits over baby powder

Separately, the company said in May it has resolved 95% of claims its baby powder was tainted with asbestos and caused mesothelioma, a type of cancer that forms in tissues around the heart and lungs

Johnson & Johnson Q2 profit beats expectations as forecast cut on M&A costs

Adjusted earnings for the quarter were $2.82 a share, the New Brunswick, New Jersey-based company said Wednesday in a statement, beating analysts' average estimate by 11 cents

J&J subsidiary proposes paying $6.48 bn over 25 yrs to settle talc lawsuits

A subsidiary of Johnson and Johnson is now proposing paying approximately USD 6.48 billion over 25 years as part of a settlement to cover allegations that its baby powder containing talc caused ovarian cancer. The lawsuits filed against JandJ had alleged its talcum powder caused users to develop ovarian cancer, through use for feminine hygiene, or mesothelioma, a cancer that strikes the lungs and other organs. JandJ said that the reorganization plan for the subsidiary that was being announced on Wednesday was significantly different from the previous reorganization that was announced. Those differences include a three-month solicitation period during which ovarian claimants can vote for or against the plan. This is something that was denied in prior bankruptcy cases, the company said. And if 75 per cent of claimants vote in favor of the plan, a subsidiary may file a prepackaged Chapter 11 bankruptcy to secure its confirmation. The remaining pending personal injury lawsuits that rel

Johnson & Johnson to buy equipment maker Shockwave Medical for $12.5 bn

Under the deal, J&J would pay $335 per share in cash for the medical device maker. The offer price implies a 4.7% premium to Shockwave's last close of $319.99 on Thursday

J&J's immune disorder drug succeeds in mid and late-stage studies

The drug, nipocalimab, significantly reduced symptoms of generalized myasthenia gravis (gMG) in a late-stage study, and in a mid-stage study helped reduce Sjogren's disease severity, J&J said

P&G Hygiene Q2 result: Profit jumps as lower costs offset dip in sales

BENGALURU (Reuters) - Indian consumer goods maker Procter & Gamble Hygiene and Health Care reported higher second-quarter net profit on Wednesday, as lower costs countered a small drop in sales.

Talc lawsuit: J&J sets up 3rd bankruptcy bid by moving unit to Texas

The company filed a request last month with the Texas secretary of state's office to relocate its LTL Management unit to Austin and rename it ahead of a Chapter 11 filing in the state

Johnson & Johnson sees 2024 sales growth slowing as top drug faces rivals

The pharma and medical devices giant will soon lose its exclusivity with psoriasis treatment Stelara, which accounted for a fifth of its drug sales in the third quarter

J&J weighs third bankruptcy try to settle baby powder cancer case

Attorneys for some plaintiffs opposed the idea of a return to bankruptcy court

J&J raises profit forecast as it bets on cancer drugs, medical devices

Shares of J&J, which recently spun off its consumer health unit to focus on drugs and medical devices, rose about 2% in premarket trading

Johnson&Johnson ordered to pay $18.8 mn in California talc-cancer trial

Jurors in state court in state court in Oakland concluded Tuesday that J&J's baby powder helped cause Anthony Hernandez Valadez's mesothelioma, a specific type of cancer linked to asbestos exposure